Arcus Biosciences Balance Sheet
NYSE: RCUSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Arcus Biosciences financial position
At the end of fiscal 2025, Arcus Biosciences reported total assets of $1.14 billion, down 1.0% from a year earlier against total liabilities of $508.0 million. Shareholders' equity stood at $631.0 million, or 55.4% of assets. The company held $222.0 million in cash and equivalents against $99.0 million of debt, a net cash position of $123.0 million.
The current ratio (current assets divided by current liabilities) was 4.36, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.16.
Summary generated from market data by MetaCap's automated system. Methodology
Arcus Biosciences balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 222.00M | 150.00M | 127.00M | 206.00M | 148.00M | 173.41M | 57.94M | 71.06M | 98.43M | 65.16M |
| Short-Term Investments | 759.00M | 828.00M | 632.00M | 803.00M | 351.00M | 555.23M | 130.33M | 185.48M | 77.28M | — |
| Total Current Assets | 1.01B | 1.02B | 831.00M | 1.07B | 1.26B | 735.82M | 192.71M | 258.95M | 176.87M | — |
| Property, Plant & Equipment | 40.00M | 47.00M | 51.00M | 35.00M | 32.00M | 10.81M | 9.33M | 11.11M | 11.23M | — |
| Long-Term Investments | 29.00M | 14.00M | 107.00M | 129.00M | 182.00M | 6.44M | — | — | — | — |
| Total Assets | 1.14B | 1.15B | 1.09B | 1.34B | 1.59B | 772.29M | 203.11M | 274.93M | 190.49M | — |
| Accounts Payable | 42.00M | 18.00M | 17.00M | 20.00M | 10.00M | 15.68M | 4.70M | 3.10M | 3.82M | — |
| Total Current Liabilities | 231.00M | 226.00M | 184.00M | 193.00M | 166.00M | 121.67M | 22.71M | 16.93M | 12.73M | — |
| Long-Term Debt | 99.00M | 48.00M | 0 | — | — | — | — | — | — | — |
| Total Liabilities | 508.00M | 665.00M | 633.00M | 688.00M | 750.45M | 269.99M | 39.27M | 39.98M | 36.62M | — |
| Shareholders' Equity | 631.00M | 485.00M | 462.00M | 657.00M | 842.00M | 502.00M | 164.00M | 234.94M | -72.33M | -19.99M |
| Retained Earnings | -1.49B | -1.13B | -849.00M | -542.00M | -275.00M | -328.18M | -205.33M | -122.83M | -73.23M | — |
| Total Debt | 99.00M | 48.00M | 0 | — | — | — | — | — | — | — |
| Net Cash (Debt) | 882.00M | 930.00M | 759.00M | 1.01B | 499.00M | 728.65M | 188.27M | 256.54M | 175.70M | 65.16M |
| Shares Outstanding | 125.30M | 92.20M | 75.50M | 72.90M | 70.80M | 65.11M | 45.93M | 44.54M | 4.09M | — |
This table shows 10 annual periods of Arcus Biosciences's balance sheet, from FY 2025 back to FY 2016, across 15 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow RCUS's reporting calendar. What is a balance sheet?